Silencing assays revealed that siEGFP-18 was significantly more potent than either siEGFP-27 or siEGFP-19 (Determine 4D)

Silencing assays revealed that siEGFP-18 was significantly more potent than either siEGFP-27 or siEGFP-19 (Determine 4D). Together, these results showed that our approach indeed recognized the most potent siRNAs from your libraries. == The approach STAT3-IN-1 eliminates potential toxic siRNAs during screening == A substantial quantity of siRNAs can induce sequence unspecific cytotoxicity that also greatly correlates STAT3-IN-1 with off-target effects (20). side effects of siRNAs. == INTRODUCTION == RNA interference (RNAi) is an evolutionarily conserved mechanism for silencing gene expression via the sequence-specific degradation of target RNA. In the past years, RNAi has become a very powerful genetic tool for functional genomics study, and its rapid advance has led to the development of RNAi-based therapeutics for treating human diseases. A prerequisite in the use of RNAi as a reverse genetic tool or as a therapeutic is the choice of potent and specific small interfering RNA (siRNA) sequences. It has been reported that the application of low doses of potent siRNAs/short hairpin RNAs (shRNAs)in vivogreatly reduced their off-target effects and cytotoxicities (1,2), which Mouse monoclonal to CD62P.4AW12 reacts with P-selectin, a platelet activation dependent granule-external membrane protein (PADGEM). CD62P is expressed on platelets, megakaryocytes and endothelial cell surface and is upgraded on activated platelets.This molecule mediates rolling of platelets on endothelial cells and rolling of leukocytes on the surface of activated endothelial cells are the two major issues in RNAi applications. Further studies also revealed that low-doses of potent siRNAs/shRNAs minimized the possibility of competition with endogenous miRNA machinery (2). At present, for RNAi studies most researchers use the reported algorithms simply to design several siRNA/shRNA sequences per target gene for synthesis (1,3,4). However, since the RNAi mechanism is currently not fully illustrated, it is acknowledged that this RNAi potency of such empirically designed siRNAs is usually uncertain until experimentally validated, and highly potent siRNAs, which would be particularly useful for therapeutics, could not be predicted by the current design algorithms (1,5,6). Accordingly, alternative approaches have been made to define effective siRNAs/shRNAs for RNAi. The siRNAs as pools have been directly generated by the enzymatic digestion of double-stranded RNAs (dsRNAs), and have confirmed effective for silencing target genes (7,8). Furthermore, effective siRNAs/shRNAs could be recognized from RNAi libraries through high-throughput STAT3-IN-1 screening (5,6), or by experimental defining, such as by systematically extending the duplex length of siRNAs beyond longer than 1921 nt (9). Here we describe a forward approach for the strong selection of the most effective siRNAs from RNAi libraries that were delivered directly into an entire populace of mammalian cells via bacterial invasion. We show that instead of the usual laborious cell-based assays of all wells in all plates, we performed the entire process of both delivering siRNA library and screening siRNAs in a single container (dish), and then immediately recognized the most potent and nontoxic siRNAs from surviving cells upon drug selection. Thus we exhibited the potential of this method for the strong discovery of the most suitable siRNAs for functional genomics studies and the development of RNAi-based therapeutics. == MATERIALS AND METHODS == == The siRNA library construction == To construct a siRNA library, we first replaced human H1-U6 polymerase III promoter cassette in pHippy (10) (a gift of Dr STAT3-IN-1 Moon, University or college of Washington) with the double-promoter siRNA cassette of pFIV-H1/U6-Puro-siRNA (System Bioscience, CA) to produce pHippy-SBI. We digested the vector with BbsI and inserted two annealed oligos (Sense: 5-AAAATATTAAGCTTAATATTC-3 and Antisense: 5-AAAAGAATATTAAGCTTAATA -3) into the digested pHippy-SBI vector to position two SspI sites for blunt insertion of DNA fragments. The altered vector designated pHippy-SspI. To construct siRNA libraries, we PCR-amplified a 1.3 kb-cDNA fragment encoding the N-terminus of the major vault protein (MVP) gene or a 700 bp-cDNA fragment encoding theegfpgene with the two specific primers for the each gene. The amplified PCR products were partially digested by DNase I in the presence of 1 mM MnCl2. We isolated DNA fragments (2030 pb) from gel, and ends-filled with dNTPs using T4 DNA polymerase to make blunt ends. The 5 phosphates of the packed DNA fragments were removed with calf intestinal phosphatase. We ligated the DNA fragments with SspI digested pHippy-SspI vector at 16C overnight with DNA ligase, and redigested the ligated products with SspI for 3 h at 37C to eliminate the self-ligated pHippy-SspI vector. We transformed the ligation reaction intoEscherichia coliDH5. After overnight cultivation on plates, the library plasmid DNA was purified and transformed intoE. coliBT203 in which theasdgene was deleted and plasmid pGBinv-hly was transformed for delivery of siRNA libraries into mammalian cells via bacterial invasion (5). == Synthesis of siRNA duplex == We chemically synthesized siRNAs (Integrated DNA Technologies Inc.,) or synthesized themin vitroby T7 RNA polymerase using the Silencer siRNA construction kit (Ambion). == Evaluation of RNAi potency == For siMVPs, we constructed a pEGFP-MVP vector by directly inserting the 1.3-kb coding sequence of theMVPgene right after the stop codon of theegfpgene at theHindIII site for expression ofegfp-MVPhybrid transcripts in cells. We transfected the synthesized siRNAs using Lipofectamine 2000 (Invitrogen) into mammalian.